Surveillance study of candidemia in cancer patients in North China

Medical Mycology

Volumn 51, Issue 4, 2013, Pages 378-384

  Li, Ding ^a   Zhang, Wenfang ^a   Zheng, Shan ^a   Ma, Zhenyi ^c,d   Zhang, Peng ^a   Liu, Zhe ^a,b,c  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b Tianjin Key Laboratory of Medical Epigenetics   (China)

^c BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^d School of Basic Medical Sciences   (China)

Author keywords

Cancer patients; Candidemia; Digestive system; Epidemiology; Neoplasms; Risk factors

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; ANTIFUNGAL AGENT; PYRROLE DERIVATIVE;

ADULT; AGED; CANCER CLASSIFICATION; CANCER PATIENT; CANCER SURGERY; CANDIDA ALBICANS; CANDIDA FAMATA; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; CANDIDIASIS; CHINA; CLAVISPORA LUSITANIAE; FEMALE; FUNGAL STRAIN; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; REVIEW; RISK FACTOR; CANDIDA; CLASSIFICATION; COMPLICATION; DEMOGRAPHY; DRUG EFFECTS; EPIDEMIOLOGY; GEOGRAPHY; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MIDDLE AGED; NEOPLASMS; RETROSPECTIVE STUDY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; AZOLES; CANDIDA; CANDIDEMIA; CHINA; DEMOGRAPHY; FEMALE; GEOGRAPHY; HUMANS; INCIDENCE; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84876220256     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.3109/13693786.2012.727481     Document Type: Review

References (38)

1. Pfaller MA, Moet GJ, Messer SA, Jones RN, Castanheira M. Geographic variations in species distribution and echinocandin and azole antifungal resistance rates among Candida bloodstream infection isolates: report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009). J Clin Microbiol 2011; 49: 396-399.
2. Asmundsdottir LR, Erlendsdottir H, Haraldsson G, et al. Molecular epidemiology of candidemia: evidence of clusters of smoldering nosocomial infections. Clin Infect Dis 2008; 47: 17-24.
3. Nucci M, Queiroz-Telles F, Tobon AM, Restrepo A, Colombo AL. Epidemiology of opportunistic fungal infections in Latin America. Clin Infect Dis 2010; 51: 561-570.
4. Colombo AL, Nucci M, Park BJ, et al. Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centers. J Clin Microbiol 2006; 44: 2816-2823.
5. Sandven P, Bevanger L, Digranes A, et al. Candidemia in Norway (1991 to 2003): results from a nationwide study. J Clin Microbiol 2006; 44: 1977-1981.
6. Arendrup MC, Bruun B, Christensen JJ, et al. National surveillance of fungemia in Denmark (2004 to 2009). J Clin Microbiol 2011; 49: 325-334.
7. Wu JQ, Zhu LP, Ou XT, et al. Epidemiology and risk factors for non- Candida albicans candidemia in non-neutropenic patients at a Chinese teaching hospital. Med Mycol 2011; 49: 552-555.
8. DiazGranados CA, Martinez A, Deaza C, Valderrama S. An outbreak of Candida spp. bloodstream infection in a tertiary care center in Bogota, Colombia. Braz J Infect Dis 2008; 12: 390-394.
9. Klevay MJ, Ernst EJ, Hollanbaugh JL, et al. Therapy and outcome of Candida glabrata versus Candida albicans bloodstream infection. Diagn Microbiol Infect Dis 2008; 60: 273-277.
10. Spiliopoulou A, Dimitriou G, Jelastopulu E, et al. Neonatal intensive care unit candidemia: epidemiology, risk factors, outcome, and critical review of published case series. Mycopathologia 2012; 173: 219-228.
11. Bassetti M, Taramasso L, Nicco E, et al. Epidemiology, species distribution, antifungal susceptibility and outcome of nosocomial candidemia in a tertiary care hospital in Italy. PLoS One 2011; 6: e24198.
12. Ortega M, Marco F, Soriano A, et al. Candida species bloodstream infection: epidemiology and outcome in a single institution from 1991 to 2008. J Hosp Infect 2011; 77: 157-161.
13. Zirkel J, Klinker H, Kuhn A, et al. Epidemiology of C andida blood stream infections in patients with hematological malignancies or solid tumors. Med Mycol 2012; 50: 50-55.
14. Pfaller MA, Castanheira M, Messer SA, Moet GJ, Jones RN. Variation in Candida spp. distribution and antifungal resistance rates among bloodstream infection isolates by patient age: report from the SENTRY Antimicrobial Surveillance Program (2008-2009). Diagn Microbiol Infect Dis 2010; 68: 278-283.
15. Trick WE, Fridkin SK, Edwards JR, et al. Secular trend of hospitalacquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 2002; 35: 627-630.
16. Pfaller MA, Diekema DJ, Gibbs DL, et al. G eographic variation in the frequency of isolation and fluconazole and voriconazole susceptibilities of Candida glabrata: an assessment from the ARTEMIS DISK Global Antifungal Surveillance Program. Diagn Microbiol Infect Dis 2010; 67: 162-171.
17. Lee JS, Shin JH, Lee K, et al. Species distribution and susceptibility to azole antifungals of Candida bloodstream isolates from eight university hospitals in Korea. Yonsei Med J 2007; 48: 779-786.
18. Odds FC, Hanson MF, Davidson AD, et al. One year prospective survey of Candida bloodstream infections in Scotland. J Med Microbiol 2007; 56: 1066-1075.
19. Agvald-Ohman C, Klingspor L, Hjelmqvist H, Edlund C. Invasive candidiasis in long-term patients at a multidisciplinary intensive care unit: Candida colonization index, risk factors, treatment and outcome. Scand J Infect Dis 2008; 40: 145-153.
20. Barberino MG, Silva N, Reboucas C, et al. E valuation of blood stream infections by Candida in three tertiary hospitals in Salvador, Brazil: a case-control study. Braz J Infect Dis 2006; 10: 36-40.
21. Boktour MR, Kontoyiannis DP, Hanna HA, et al. Multiple-species candidemia in patients with cancer. Cancer 2004; 101: 1860-1865.
22. Clinical and Laboratory Standards Institute. R eference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts, Approved Standard, 2nd edn. Wayne, PA: National Committee for Clinical Laboratory Standards, 2002.
23. Clinical and Laboratory Standards Institute. R eference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts, Approved standard, 3nd edn. Wayne, PA: National Committee for Clinical Laboratory Standards, 2008.
24. Klingspor L, Tornqvist E, Johansson A, et al. A prospective epidemiological survey of candidaemia in Sweden. Scand J Infect Dis 2004; 36: 52-55.
25. Motta AL, Almeida GM, Almeida Junior JN, Burattini MN, Rossi F. Candidemia epidemiology and susceptibility profile in the largest Brazilian teaching hospital complex. Braz J Infect Dis 2010; 14: 441-448.
26. Dimopoulos G, Velegraki A, Falagas ME. A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece. Antimicrob Agents Chemother 2009; 53: 1242- 1244.
27. Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis 2003; 3: 685-702.
28. Pittet D, Monod M, Suter PM, Frenk E, Auckenthaler R. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 1994; 220: 751-758.
29. Nucci M, Anaissie E. Revisiting the source of candidemia: skin or gut? Clin Infect Dis 2001; 33: 1959-1967.
30. Holley A, Dulhunty J, Blot S, et al. Temporal trends, risk factors and outcomes in albicans and non- albicans candidaemia: an international epidemiological study in four multidisciplinary intensive care units. Int J Antimicrob Agents 2009; 33: 554-557.
31. Cheng MF, Yang YL, Yao TJ, et al. Risk factors for fatal candidemia caused by Candida albicans and non- albicans Candida species. BMC Infect Dis 2005; 5: 22-26.
32. Leroy O, Mira JP, Montravers P, et al. Comparison of a lbicans vs. non-albicans candidemia in French intensive care units. Crit Care 2010; 14: R98.
33. Pfaller MA, Moet GJ, Messer SA, Jones RN, Castanheira M. Candida bloodstream infections: comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009. Antimicrob Agents Chemother 2011; 55: 561-566.
34. Godoy P, Tiraboschi IN, Severo LC, et al. Species distribution and antifungal susceptibility profile of Candida spp. bloodstream isolates from Latin American hospitals. Mem Inst Oswaldo Cruz 2003; 98: 401-405.
35. Pfaller MA, Diekema DJ, Gibbs DL, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-year analysis of susceptibilities of noncandidal yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol 2009; 47: 117-123.
36. Tan TY, Tan AL, Tee NW, Ng LS. A retrospective analysis of antifungal susceptibilities of Candida bloodstream isolates from Singapore hospitals. Ann Acad Med Singapore 2008; 37: 835-840.
37. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007; 20: 133-163.
38. Atkinson BJ, Lewis RE, Kontoyiannis DP. C andida lusitaniae fungemia in cancer patients: risk factors for amphotericin B failure and outcome. Med Mycol 2008; 46: 541-546.